T-cell therapy for advanced pancreatic cancer with KRAS mutations
Part of Cancer clinical trials.
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with metastatic or locally advanced pancreatic cancer (PDAC).
- Your tumor has a KRAS G12V or KRAS G12D mutation, confirmed by a biopsy.
- You have a specific HLA type (tissue marker) that matches the therapy.
- You have seen benefit from standard treatments and your disease hasn't worsened.
- Your cancer can be measured by scans, and you haven't had brain metastases or another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
This trial tests an experimental treatment that uses your own immune cells (T cells) that have been specially changed to attack cancer cells with a certain genetic mutation (KRAS G12D). It may be an option for people with advanced cancer that has not responded to standard treatments.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.